News | June 14, 2010

Rb-82 Radiotracer Grows at Rapid Rate

Rb-82 Radiotracer Grows at Rapid Rate

June 14, 2010 – A radio tracer is quickly gaining popularity among cardiologists in the United States.

Bracco Diagnostics Inc. recently announced that its CardioGen-82 (rubidium Rb 82 generator) is achieving unprecedented growth in the United States. Over the past five years, CardioGen-82 has experienced double-digit year-over-year growth, with a marked increase recorded in the past nine months. [1] Cardiologists, radiologists, and nuclear medicine physicians will perform an estimated 145,000 positron emission tomography (PET) myocardial perfusion imaging (MPI) procedures in 2010 using CardioGen-82. [2]

Several key factors have contributed to this growth, including increasing momentum for the modality of cardiac PET, publication of key clinical data, and improvements in PET hardware/software technology and accessibility.

CardioGen-82 is the only FDA-approved generator-based PET MPI tracer reimbursed for the evaluation of coronary artery disease (CAD). [3]

As the significant shortage of SPECT (single photon emission computed tomography) MPI tracers made using Mo-99 continues, many nuclear cardiology labs have adopted cardiac PET with CardioGen-82 as a standard of patient care. With the closing of both National Research Universal’s Chalk River reactor in Canada – the source of more than half the world’s supply of Mo-99 – and the Petten reactor in the Netherlands, and no short-term fix in sight, health care providers face significant pressure to find alternate ways to meet the needs of their CAD patients beyond the standard practices they have typically and previously employed.

Since PET MPI procedures can be performed in as little as 30 minutes or less, there are great efficiencies offered by this technique. [4, 5] “The reduced scan time compared with SPECT helps to improve patient satisfaction,” says referring cardiologist Kyle Richards, M.D. of Pioneer Valley Cardiology in Springfield, Mass.

Moreover, PET MPI offers greater interpretive certainty for imagers, according to a publication in the Journal of Nuclear Cardiology by Tim Bateman, M.D. of Cardiovascular Consultants in Kansas City, Mo., and his colleagues: “A significantly lower percent (81 percent) of SPECT scans were able to be interpreted as definitely normal or abnormal compared with 96 percent of PET images (p=.0008).” [5]

For more information: www.cardiogen.com.

References:

[1] Bracco Sales Data on file

[2] Bio-Tech Systems, Inc. PET Market Report July 2009

[3] Medicare National Coverage Determination 220.6.1

[4] Dorbala S., Hachamovitch R., Curillova Z., et al. “Incremental Prognostic Value of Gated Rb-82 Positron Emission Tomography Myocardial Perfusion Imaging Over Clinical Variables and Rest LVEF.” Journal of the American College of Cardiology. 2009;2;846-854.

[5] Bateman T.M., Heller G.V., McGhie A.l., et al. “Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT.” Journal of Nuclear Cardiology. 2006;13:24-33.

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....